Product logins

Find logins to all Clarivate products below.


Dyslipidemia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Dyslipidemia (US)

Dyslipidemia, characterized by abnormal lipid levels, plays a pivotal role in the development of cardiovascular (CV) disease. Physicians address this risk with various lipid-modifying therapies such as statins, ezetimibe, fibrates, omega-3 fatty acids, and PCSK9 inhibitors. Statins are particularly notable for their favorable risk-benefit profile and strong evidence of their ability to reduce CV morbidity and mortality. Nevertheless, the treatment landscape extends beyond statins; numerous later-line therapies offer additional options for lipid management and reduction in CV risk. Using longitudinal claims data analysis, we explore the treatment of newly diagnosed and recently treated dyslipidemia patients in the United States.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed dyslipidemia patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed dyslipidemia patients?
  • How have PCSK9 inhibitors (Praluent, Repatha, and Leqvio) been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of dyslipidemia patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
  • What percentage of dyslipidemia patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States

Key companies: Amarin, Esperion Therapeutics, Amgen, Novartis, Regeneron, Merck & Co., Pfizer, AstraZeneca, Kowa Pharmaceuticals, Medicure Pharmaceuticals

Key drugs: Statins, fibrates, Leqvio, Nexlizet, and Repatha

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Key feature

Dashboard featuring interactive visuals, easy navigation, and expanded analyses

Related Market Assessment Reports

Report
Insomnia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Insomnia (US)
Insomnia is a prevalent sleep disorder characterized by daytime dysfunction resulting from one or more sleep problems. The treatment of insomnia is highly individualized, and physicians consider…
Report
Psoriasis – Geographic Focus: China – Psoriasis | China In-Depth | China | 2025
Psoriasis is a chronic dermatologic condition with rising prevalence in China, particularly in urban areas where heightened awareness and improved access to care have led to higher diagnosis rates…
Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Breast Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
CDK4/6 inhibitors (Pfizer’s palbociclib, Novartis’s ribociclib, and Eli Lilly’s abemaciclib) combined with endocrine therapy are central to the treatment of metastatic HR-positive / HER2-…
Report
Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes – China In-Depth (China)
In China, type 2 diabetes (T2D) continues to be a leading public health concern, with the highest global prevalence. Biguanides continue to dominate the market, but the use of SGLT-2 inhibitors and…